Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Metaraminol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | MIF | P14174 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.78 |
| ▸ | LMNA | P02545 | 6/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaraminol SCHEMBL29379078 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL11417827 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL136778 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL19169701 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL31144506 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL4262898 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL5172992 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL3148038 | 0.98 | ADRB1 (0.96) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL10892040 | 0.98 | ADRB1 (0.96) | ADRB1ADRA1AMIFHTR2AHTR2B | |
| Metaraminol SCHEMBL16241612 | 0.98 | ADRB1 (0.96) | ADRB1ADRA1AMIFHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3946547-B1 | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250058094-A1 | DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC. | 2025-02-20 | — | — | US | disclosed |
| US-12194263-B2 | Devices and methods for delivery of pharmaceutical compositions | Pocket Naloxone Corp. (US) | 2025-01-14 | — | — | US | disclosed |
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | 3I, LP | 2022-09-15 | — | — | US | disclosed |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220062602-A1 | DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS | PINOVA THERAPEUTICS INC. | 2022-03-03 | — | — | US | disclosed |
| EP-3946547-A1 | DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS | Pocket Naloxone Corp. (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241509-B2 | Ligands for imaging cardiac innervation | LANTHEUS MEDICAL IMAGING, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11191934-B2 | Devices and methods for delivery of pharmaceutical compositions | Pocket Naloxone Corp. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20040091981-A1 | Process for the production of optically active beta-amino alcohols | DAIICHI FINE CHEMICAL CO., LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1273665-A1 | PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | Daiichi Fine Chemical Co., Ltd. (JP) | 2003-01-08 | — | — | EP | disclosed |
| WO-1999064861-A2 | METHOD OF IDENTIFYING ANTIDEPRESSANT COMPOUNDS | UNIVERSITY COLLEGE LONDON (GB) | 1999-12-16 | — | — | WO | disclosed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0291751-B1 | PHARMACEUTICAL MIXTURE PREPARATION | Wilhelm, Gerhard, Dr. (DE) | 1992-03-11 | — | — | EP | disclosed |
| EP-0291751-A2 | Pharmaceutical mixture preparation | Wilhelm, Gerhard, Dr. (DE) | 1988-11-23 | — | — | EP | disclosed |
| US-4619823-A | Radioactive iodine labeled metaraminol and diagnostic agent containing platelets labeled therewith | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1986-10-28 | — | — | US | disclosed |
| EP-0103830-A2 | Phenylethylemine derivatires as growth stimulators | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220287992-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | DNPEP, PEPD, CEL | ADRA1A 3677/4885ADRA1B 3531/4885ADRB1 3496/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | ADRA1A 1441/4885ADRA1B 2060/4885ADRB1 1514/4885 |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | OPRK1, OPRL1, OPRM1 | ADRA1A 372/4885ADRA1B 511/4885ADRB1 393/4885 |
| US-11241509-B2 | Ligands for imaging cardiac innervation | TNNT2, PNMT, TNNC1 | ADRA1A 19/4885ADRA1B 15/4885ADRB1 7/4885 |
| US-11400062-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | ADRA1A 849/4885ADRA1B 566/4885ADRB1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.